Fc Engineering: Design, Expression, and Functional Characterization of Antibody Variants with Improved Effector Function
- 12 July 2012
- book chapter
- Published by Springer Nature
- Vol. 907, 519-536
Abstract
Today monoclonal antibodies are widely used in cancer therapy. However, clinical experience as well as translational research into antibodies’ pharmacology and effector mechanisms has identified limitations of antibody therapy, including inefficient effector cell recruitment or initiation of complement-dependent cytotoxicity (CDC). These insights opened alleys for further improvement of antibodies’ immunomodulatory functions. While second generation antibodies were predominantly engineered to reduce immunogenicity, progress in antibody engineering now enables the generation of antibodies with novel interesting features. The introduction of Fc engineering technologies offers the potential to tailor Fc-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), CDC or phagocytosis. Approaches to improve Fc-mediated effector mechanisms by Fc-engineering allow for the design of so-called “fit-for-purpose” antibodies or antibody-derivatives, hopefully overcoming some limitations of current forms of antibody therapy.Keywords
This publication has 29 references indexed in Scilit:
- Molecular engineering to improve antibodies’ anti-lymphoma activityBest Practice & Research Clinical Haematology, 2011
- Post-translational Modifications Differentially Affect IgG1 Conformation and Receptor BindingMolecular & Cellular Proteomics, 2010
- Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functionsmAbs, 2010
- Double knockdown of α1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCCBMC Biotechnology, 2007
- Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor CellsIn vitroand Controls Tumor ExpansionIn vivovia Low-Affinity Activating Fcγ ReceptorsCancer Research, 2007
- Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular ToxicityJournal of Biological Chemistry, 2002
- Reshaping human antibodies for therapyNature, 1988
- A hapten-specific chimaeric IgE antibody with human physiological effector functionNature, 1985
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975
- Croonian lecture.—On immunity with special reference to cell lifeProceedings of the Royal Society of London, 1900